研究業績

論文・出版

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial (JBCRG-22)


Norikazu Masuda, Hiroko Bando, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R. Kataoka, Ryuji Uozumi, Shinji Ohno, Masakazu Toi


Breast Cancer Research and Treatment , 2021 March, 188: 117–131


https://doi: 10.1007/s10549-021-06184-w

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: A multicenter, single arm, phase II study (JBCRG-M03 study)


Toshinari Yamashita, Hidetoshi Kawaguchi, Norikazu Masuda, Masahiro Kitada, Kazutaka Narui, Masaya Hattori, Tetsuhiro Yoshinami, Nobuki Matsunami, Kazuhiro Yanagihara, Teru Kawasoe, Takeshi Nagashima, Hiroko Bando, Hiroshi Yano, Yoshie Hasegawa, Rikiya Nakamura, Masahiro Kashiwaba, Satoshi Morita, Shinji Ohno, Masakazu Toi


Investigational New Drugs. 2021; 39(1): 217-225.


https://doi.org/10.1007/s10637-020-00991-6

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study


Yutaka Yamamoto, Hiroyasu Yamashiro, Uhi Toh, Naoto Kondo, Rikiya Nakamura, Masahiro Kashiwaba, Masato Takahashi, Koichiro Tsugawa, Takashi Ishikawa, Takahiro Nakayama, Shoichiro Ohtani, Toshimi Takano, Tomomi Fujisawa, Tatsuya Toyama, Hidetoshi Kawaguchi, Kojiro Mashino, Yuichi Tanino, Satoshi Morita, Masakazu Toi, Shinji Ohno


Breast Cancer 2021 Jan; 28(1):145-160


https://doi.org/10.1007/s12282-020-01138-4

Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial


Moe Tsuda; Hiroshi Ishiguro; Naoko Toriguchi; Norikazu Masuda; Hiroko Bando; Masahiro Ohgami; Masato Homma; Satoshi Morita; Naohito Yamamoto; Katsumasa Kuroi; Yasuhiro Yanagita; Toshimi Takano; Satoru Shimizu; Masakazu Toi


Cancer Medicine 2020 Dec;9(24):9246-9255


https://doi.org/10.1002/cam4.3528

Outcomes of Trastuzumab Therapy in HER2-Positive Early Breast Cancer Patients: Extended Follow-up of JBCRG-Cohort Study 01


Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, Naohito Yamamoto, Reiki Nishimura, Shoichiro Ohtani, Nobuaki Sato, Masato Takahashi, Takako Kamio, Kosuke Yamazaki, Tsuyoshi Saito, Makoto Kato, Tecchuu Lee, Katsumasa Kuroi, Toshimi Takano, Shinji Yasuno, Satoshi Morita, Shinji Ohno, Masakazu Toi, JBCRG-C01 Collaborative Group Collaborators,


Breast Cancer. 2020 Jul; 27(4): 631-641. Epub 2020 Feb 14.


https://doi.org/10.1007/s12282-020-01057-4

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority (phase III) trial in Japan (JBCRG-M06/EMERALD)


Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno


Trials. 2020 May; 21(1): 391.


https://doi.org/10.1186/s13063-020-04341-y

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer (JBCRG-09)


Hiroshi Ishiguro, Norikazu Masuda, Nobuaki Sato, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka-Mizuno, and Masakazu Toi


Breast Cancer Research and Treatment. 2020; 180: 715–724.


https://doi.org/10.1007/s10549-020-05590-w

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer (JBCRG-20 study)


Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Eiji Suzuki, Rikiya Nakamura, Hiroko Bando, Yoshinori Ito, Kazushige Ishida, Takashi Yamanaka, Katsumasa Kuroi, Hiroyuki Yasojima, Hiroi Kasai, Tsuyoshi Takasuka, Takaki Sakurai, Tatsuki R. Kataoka, Satoshi Morita, Shinji Ohno, Masakazu Toi


Breast Cancer Research and Treatment. 2020; 180: 135–146.


https://doi.org/10.1007/s10549-020-05524-6

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study


Takayuki Ueno, Norikazu Masuda, Nobuaki Sato, Shoichiro Ohtani, Jun Yamamura, Nobuki Matsunami, Masahiro Kashiwaba, Toshimi Takano, Masato Takahashi, Koji Kaneko, Shinji Ohno, Satoshi Morita, and Masakazu Toi


Japanese Journal of Clinical Oncology, 2020, 50(1)3–11


https://doi.org/10.1093/jjco/hyz119

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study


Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno


Breast Cancer. 2020; 27: 389–398.


https://doi.org/10.1007/s12282-019-01029-3

前のページへ 次のページへ
任意団体JBCRG 研究業績